Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azelastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 17/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 17/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 17/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azelastine SCHEMBL4240 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1ADRA1BHRH3KCNH2 | |
| Azelastine SCHEMBL17803891 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1ADRA1BHRH3KCNH2 | |
| Azelastine SCHEMBL17223862 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1ADRA1BHRH3KCNH2 | |
| Azelastine SCHEMBL30910968 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1ADRA1BHRH3KCNH2 | |
| Azelastine SCHEMBL4239 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1ADRA1BHRH3KCNH2 | |
| Azelastine SCHEMBL4433245 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1ADRA1BHRH3KCNH2 | |
| Azelastine SCHEMBL36770 | 0.99 | ADRA1A (1.00) | ADRA1AHRH1ADRA1BHRH3KCNH2 | |
| Azelastine SCHEMBL19458799 | 0.99 | ADRA1A (1.00) | ADRA1AHRH1ADRA1BHRH3KCNH2 | |
| Azelastine SCHEMBL4012083 | 0.99 | ADRA1A (0.98) | ADRA1AHRH1ADRA1BHRH3KCNH2 | |
| Azelastine SCHEMBL36771 | 0.99 | ADRA1A (1.00) | ADRA1AHRH1ADRA1BHRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4247331-B1 | ORODISPERSIBLE POWDER COMPOSITION COMPRISING AN ANTIHISTAMINE COMPOUND | BIOPHARMA SYNERGIES S L (ES) | 2025-10-08 | — | — | EP | claimed |
| EP-4302829-B1 | PEPTIDE FOR USE IN PREVENTING OR TREATING MACULAR DEGENERATION | STEALTH BIOTHERAPEUTICS INC (US) | 2025-05-21 | — | — | EP | claimed |
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | UNIVERSITY OF WASHINGTON | 2025-04-03 | — | — | US | claimed |
| US-20250041208-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2025-02-06 | — | — | US | claimed |
| EP-4463155-A2 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | University of Washington (US) | 2024-11-20 | — | — | EP | claimed |
| EP-3508501-B1 | USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS | H LUNDBECK AS (DK) | 2024-11-06 | — | — | EP | claimed |
| EP-4444277-A1 | NEW INJECTABLE COMBINATION FORMULATION | Nanexa AB (SE) | 2024-10-16 | — | — | EP | claimed |
| EP-4429635-A1 | SELF-EMULSIFYING OIL-IN-WATER MICROEMULSION OR NANOEMULSION, AND EMULSIFYING COMPOSITION | URSAPHARM Arzneimittel GmbH (DE) | 2024-09-18 | — | — | EP | claimed |
| EP-3756665-B1 | INTERVAL THERAPY FOR THE TREATMENT OF EYE DISEASES | UNIV RAMOT (IL) | 2024-08-14 | — | — | EP | claimed |
| EP-3682872-B1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-01-03 | — | — | EP | claimed |
| EP-3708178-B1 | PEPTIDE FOR USE IN PREVENTING OR TREATING MACULAR DEGENERATION | STEALTH BIOTHERAPEUTICS INC (US) | 2023-10-04 | — | — | EP | claimed |
| EP-3836905-B1 | NOVEL ORAL COMPOSITION | APILLET APS (DK) | 2023-10-04 | — | — | EP | claimed |
| EP-3794002-B1 | COMPOUNDS | ENTERPRISE THERAPEUTICS LTD (GB) | 2023-08-02 | — | — | EP | claimed |
| EP-3179982-B1 | METHOD OF INCREASING BIOAVAILABILITY AND/OR PROLONGING OPHTHALMIC ACTION OF A DRUG | SUN PHARMA ADVANCED RES CO LTD (IN) | 2023-07-19 | — | — | EP | claimed |
| WO-2023105227-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2023-06-15 | — | — | WO | claimed |
| WO-2023084038-A1 | SELF-EMULSIFYING OIL-IN-WATER MICROEMULSION OR NANOEMULSION, AND EMULSIFYING COMPOSITION | URSAPHARM ARZNEIMITTEL GMBH (DE) | 2023-05-19 | — | — | WO | claimed |
| EP-3743406-B9 | TMEM16A MODULATORS | TMEM16A LTD (GB) | 2023-03-08 | — | — | EP | claimed |
| EP-3743406-B1 | TMEM16A MODULATORS | TMEM16A LTD (GB) | 2022-12-28 | — | — | EP | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-20260085120-A1 | Carrier-PD-L1 Binding Agent Compositions for Treating Cancers | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260014147-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260007682-A1 | NASAL COMPOSITIONS COMPRISING ALCAFTADINE | ALKEM LABORATORIES LTD (IN) | 2026-01-08 | — | — | US | disclosed |
| EP-3562526-B1 | STENT MADE OF A BIODEGRADABLE MAGNESIUM ALLOY WITH A MAGNESIUM FLUORIDE COATING AND AN ORGANIC COATING | MEKO MFG E K (DE) | 2025-11-12 | — | — | EP | disclosed |
| EP-4637958-A1 | HIGH PERFORMANCE FILTER MEDIA | Hollingsworth & Vose Company (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250327082-A1 | New C5a Binding Nucleic Acids | APTARION BIOTECH AG (DE) | 2025-10-23 | — | — | US | disclosed |
| EP-4633602-A1 | NEW PHARMACEUTICAL COMPOSITIONS COMPRISING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS | Nanexa AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| US-20250312275-A1 | GAS PHASE DEPOSITION TECHNIQUE FOR PREPARATION OF PHARMACEUTICAL COMPOSITIONS | NANEXA AB (SE) | 2025-10-09 | — | — | US | disclosed |
| EP-4620474-A1 | METHOD OF TREATING A DISORDER WITH A C5A INHIBITOR | APTARION biotech AG (DE) | 2025-09-24 | — | — | EP | disclosed |
| US-12350302-B2 | Dosing regime and formulations for type B adenoviruses | Akamis Bio Limited (GB) | 2025-07-08 | — | — | US | disclosed |
| WO-2025122600-A1 | COMPOSITIONS AND METHODS FOR TREATING ABERRANT NITROSYLATION | CASE WESTERN RESERVE UNIVERSITY (US) | 2025-06-12 | — | — | WO | disclosed |
| EP-2682138-B2 | Improved pharmaceutical-coated medical products, the production thereof and the use thereof | INVATEC TECH CENTER GMBH (CH) | 2025-06-11 | — | — | EP | disclosed |
| CN-120060001-A | Lactobacillus plantarum capable of relieving allergic rhinitis and application thereof | 深圳未知君生物科技有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-20250170067-A1 | Carrier-Binding Agent Compositions and Methods of Making and Using the Same | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-05-29 | — | — | US | disclosed |
| WO-2025088039-A1 | HIGHLY CONCENTRATED DERMALLY APPLICABLE PERMETHRIN PREPARATION WITH AN INCREASED DRUG LOAD IN THE TARGET COMPARTMENT FOR IMPROVED TREATMENT OF ECTOPARASITE INFESTATION | INFECTOPHARM ARZNEIMITTEL UND CONSILIUM GMBH (DE) | 2025-05-01 | — | — | WO | disclosed |
| EP-4545067-A1 | HIGHY DOSED DERMALLY APPLICABLE PERMETHRIN PREPARATION HAVING AN INCREASED DRUGLOAD IN THE TARGET COMPARTIMENT FOR IMPROVED TREATMENT OF ECTOPARASITE INFESTATION | Infectopharm Arzneimittel und Consilium GmbH (DE) | 2025-04-30 | — | — | EP | disclosed |
| CN-119874617-A | Preparation method of azelastine hydrochloride intermediate | 贵州云峰药业有限公司 | 2025-04-25 | — | — | CN | disclosed |
| EP-4536179-A1 | GAS PHASE DEPOSITION TECHNIQUE FOR PREPARATION OF PHARMACEUTICAL COMPOSITIONS | Nanexa AB (SE) | 2025-04-16 | — | — | EP | disclosed |
| US-12274702-B2 | Nasal compositions comprising alcaftadine | ALKEM LABORATORIES LIMITED (IN) | 2025-04-15 | — | — | US | disclosed |
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | UNIVERSITY OF WASHINGTON | 2025-04-03 | — | — | US | disclosed |
| EP-2152341-B2 | ATOMIZER IN THE FORM OF AN INHALER FOR MEDICAL AEROSOL THERAPY | BOEHRINGER INGELHEIM PHARMA (DE) | 2025-04-02 | — | — | EP | disclosed |
| US-20250073219-A1 | NEW COMPOSITION COMPRISING IMMUNOMODULATORY DRUG | NANEXA AB (SE) | 2025-03-06 | — | — | US | disclosed |
| US-20250064827-A1 | NASAL COMPOSITIONS COMPRISING ALCAFTADINE | ALKEM LABORATORIES LIMITED (IN) | 2025-02-27 | — | — | US | disclosed |
| US-20250064826-A1 | NASAL COMPOSITIONS COMPRISING ALCAFTADINE | ALKEM LABORATORIES LIMITED (IN) | 2025-02-27 | — | — | US | disclosed |
| US-20250064825-A1 | NASAL COMPOSITIONS COMPRISING ALCAFTADINE | ALKEM LABORATORIES LIMITED (IN) | 2025-02-27 | — | — | US | disclosed |
| US-20250064828-A1 | NASAL COMPOSITIONS COMPRISING ALCAFTADINE | ALKEM LABORATORIES LIMITED (IN) | 2025-02-27 | — | — | US | disclosed |
| US-12220439-B2 | Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye | AKRIVISTA LLC (US) | 2025-02-11 | — | — | US | disclosed |
| US-20250041208-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2025-02-06 | — | — | US | disclosed |
| EP-4119231-B1 | LIQUID DISPENSER | APTAR RADOLFZELL GMBH (DE) | 2025-01-15 | — | — | EP | disclosed |
| US-12188021-B2 | C5a binding nucleic acids | APTARION BIOTECH AG (DE) | 2025-01-07 | — | — | US | disclosed |
| WO-2024256696-A1 | NEW INJECTABLE PHARMACEUTICAL DEPOT COMPOSITIONS | NANEXA AB (SE) | 2024-12-19 | — | — | WO | disclosed |
| US-12150955-B2 | Iodine compositions | DERMALIQ THERAPEUTICS, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| CN-119012916-A | Novel pharmaceutical compositions and methods for treating insomnia | LA药研科技公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20240384275-A1 | C5a Binding Nucleic Acids | APTARION BIOTECH AG (DE) | 2024-11-21 | — | — | US | disclosed |
| EP-4463155-A2 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | University of Washington (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20240374792-A1 | GELMA POLYMER COMPOSITIONS AND USES THEREOF | GELMEDIX INC (US) | 2024-11-14 | — | — | US | disclosed |
| EP-4444277-A1 | NEW INJECTABLE COMBINATION FORMULATION | Nanexa AB (SE) | 2024-10-16 | — | — | EP | disclosed |
| US-20240325383-A1 | Small Molecule Targeting of BRD4 for Treatment of COVID-19 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-10-03 | — | — | US | disclosed |
| EP-4429635-A1 | SELF-EMULSIFYING OIL-IN-WATER MICROEMULSION OR NANOEMULSION, AND EMULSIFYING COMPOSITION | URSAPHARM Arzneimittel GmbH (DE) | 2024-09-18 | — | — | EP | disclosed |
| CN-118647367-A | Novel injectable combination formulations | 南爱克萨股份公司 | 2024-09-13 | — | — | CN | disclosed |
| EP-4422641-A1 | PENTAGALLOYL GLUCOSE (PGG) FOR USE IN TREATMENT OF PULMONARY HYPERTENSION | Charité - Universitätsmedizin Berlin (DE) | 2024-09-04 | — | — | EP | disclosed |
| CN-118574618-A | Drug conjugates and methods of making and using the same | 艾德森特克斯治疗股份有限公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240277624-A1 | NEW FORMULATIONS COMPRISING BIOLOGIC ACTIVE DRUGS | NANEXA AB (SE) | 2024-08-22 | — | — | US | disclosed |
| US-20240277749-A1 | NEW FORMULATIONS COMPRISING AZACITIDINE | NANEXA AB (SE) | 2024-08-22 | — | — | US | disclosed |
| US-20240260949-A1 | IRRIGATION AND ASPIRATION DEVICE AND METHOD | AARDVARK MEDICAL, INC. (US) | 2024-08-08 | — | — | US | disclosed |
| CN-110678207-B | Iodine composition | 德马利克治疗公司 | 2024-08-02 | — | — | CN | disclosed |
| EP-4401802-A1 | GELMA POLYMER COMPOSITIONS AND USES THEREOF | Gelmedix, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| WO-2024137937-A1 | HIGH PERFORMANCE FILTER MEDIA | HOLLINGSWORTH & VOSE COMPANY (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240207764-A1 | HIGH PERFORMANCE FILTER MEDIA | HOLLINGSWORTH & VOSE COMPANY (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2024127019-A1 | NEW PHARMACEUTICAL COMPOSITIONS COMPRISING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS | NANEXA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024127018-A1 | NEW INJECTABLE SUSPENSION OF COATED PARTICLES | NANEXA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| US-20240173331-A1 | NASAL COMPOSITIONS COMPRISING ALCAFTADINE | ALKEM LABORATORIES LIMITED (IN) | 2024-05-30 | — | — | US | disclosed |
| EP-4351527-A1 | NEW COMPOSITION COMPRISING IMMUNOMODULATORY DRUG | Nanexa AB (SE) | 2024-04-17 | — | — | EP | disclosed |
| EP-4351529-A1 | NEW FORMULATIONS COMPRISING BIOLOGIC ACTIVE DRUGS | Nanexa AB (SE) | 2024-04-17 | — | — | EP | disclosed |
| EP-4351530-A1 | NEW FORMULATIONS COMPRISING AZACITIDINE | Nanexa AB (SE) | 2024-04-17 | — | — | EP | disclosed |
| CN-117835972-A | Novel compositions comprising immunomodulatory drugs | 南爱克萨股份公司 | 2024-04-05 | — | — | CN | disclosed |
| WO-2024063712-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AZELASTINE HCI, FLUTICASONE PROPIONATE AND RELEVANT EXCIPIENTS | PHARMACTIVE ILAC SANAYI VE TICARET A.S. (TR) | 2024-03-28 | — | — | WO | disclosed |
| EP-4338763-A1 | A PROCESS FOR 3D BIOPRINTING UTILIZING A HYDROGEL COMPRISING A WATER-SOLUBLE ELASTIN DERIVATIVE | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2024-03-20 | — | — | EP | disclosed |
| US-20240058296-A1 | MODIFIED ANTIBODY-ALBUMIN NANOPARTICLE COMPLEXES FOR CANCER TREATMENT | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-02-22 | — | — | US | disclosed |
| US-11903986-B2 | Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye | AKRIVISTA LLC (US) | 2024-02-20 | — | — | US | disclosed |
| EP-4312973-A1 | NASAL COMPOSITIONS COMPRISING ALCAFTADINE | Alkem Laboratories Limited (IN) | 2024-02-07 | — | — | EP | disclosed |
| US-11889995-B2 | Irrigation and aspiration device and method | AARDVARK MEDICAL, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| US-11883009-B2 | Irrigation and aspiration device and method | AARDVARK MEDICAL, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-11883010-B2 | Irrigation and aspiration device and method | AARDVARK MEDICAL, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| WO-2023237897-A1 | GAS PHASE DEPOSITION TECHNIQUE FOR PREPARATION OF PHARMACEUTICAL COMPOSITIONS | NANEXA AB (SE) | 2023-12-14 | — | — | WO | disclosed |
| US-20230332148-A1 | DISCONTINUOUS OLIGONUCLEOTIDE LIGANDS | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN (DE) | 2023-10-19 | — | — | US | disclosed |
| US-20230320704-A1 | IRRIGATION AND ASPIRATION DEVICE AND METHOD | AARDVARK MEDICAL, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230320703-A1 | IRRIGATION AND ASPIRATION DEVICE AND METHOD | AARDVARK MEDICAL, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230293155-A1 | IRRIGATION AND ASPIRATION DEVICE AND METHOD | AARDVARK MEDICAL, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| EP-3478356-B1 | MEDICAL DEVICE FOR TREATMENT OF A SINUS AND/OR AN EAR | SINUSAFE MEDICAL LTD (IL) | 2023-09-06 | — | — | EP | disclosed |
| EP-3612228-B1 | IODINE COMPOSITIONS | DERMALIQ THERAPEUTICS INC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4221679-A1 | COMPOSITIONS COMPRISING COMBINATIONS OF COLLAGEN OR ELASTIN POLYPEPTIDES WITH ACTIVE INGREDIENTS AND METHODS OF USING SAME | Geltor, Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| CN-116568330-A | Iron death induction for cancer treatment | 纪念斯隆-凯特琳癌症中心 | 2023-08-08 | — | — | CN | disclosed |
| US-20230233637-A1 | METHODS OF DIAGNOSING AND TREATING DRY EYE SYNDROME AND COMPOSITIONS FOR TREATING A HUMAN EYE | AKRIVISTA LLC | 2023-07-27 | — | — | US | disclosed |
| US-20230218630-A1 | COMBINATION OF ALCAFTADINE AND A CORTICOSTEROID | ALKEM LABORATORIES LIMITED (IN) | 2023-07-13 | — | — | US | disclosed |
| EP-4208204-A1 | ANTIBODY-NANOPARTICLE COMPLEXES AND METHODS FOR MAKING AND USING THE SAME | Mayo Foundation for Medical Education and Research (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20230201216-A1 | AZELASTINE AS ANTIVIRAL TREATMENT | CEBINA GmbH (AT) | 2023-06-29 | — | — | US | disclosed |
| WO-2023105227-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2023-06-15 | — | — | WO | disclosed |
| EP-4190333-A1 | AZELASTINE AS ANTIVIRAL TREATMENT | CEBINA GmbH (AT) | 2023-06-07 | — | — | EP | disclosed |
| US-20230159640-A1 | CARRIER-PD-L1 BINDING AGENT COMPOSITIONS FOR TREATING CANCERS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2023-05-25 | — | — | US | disclosed |
| US-20230158167-A1 | SITE-SPECIFIC ANTIBODY CONJUGATION AND ANTIBODY-DRUG CONJUGATE AS SPECIFIC EMBODIMENT THEREOF | AbTis Co., Ltd. (KR) | 2023-05-25 | — | — | US | disclosed |
| WO-2023084038-A1 | SELF-EMULSIFYING OIL-IN-WATER MICROEMULSION OR NANOEMULSION, AND EMULSIFYING COMPOSITION | URSAPHARM ARZNEIMITTEL GMBH (DE) | 2023-05-19 | — | — | WO | disclosed |
| US-20230142221-A1 | COMPOSITIONS AND METHODS FOR MODULATING ACE2 RECEPTOR | MUBARAK KAMAL KHAN (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2023073150-A1 | PENTAGALLOYL GLUCOSE (PGG) FOR USE IN TREATMENT OF PULMONARY HYPERTENSION | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2023-05-04 | — | — | WO | disclosed |
| EP-4164614-A1 | COMBINATION OF ALCAFTADINE AND A CORTICOSTEROID | Alkem Laboratories Limited (IN) | 2023-04-19 | — | — | EP | disclosed |
| US-11622982-B2 | Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye | AKRIVISTA LLC (US) | 2023-04-11 | — | — | US | disclosed |
| CN-111970928-B | Oil-based suspension concentrates | 拜耳作物科学股份公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-115915939-A | Antifungal polypeptides | 生物催化公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115867648-A | Extension of chemical substrates for genetic code reprogramming to include long chain carbons and cyclic amino acids | 西北大学 | 2023-03-28 | — | — | CN | disclosed |
| WO-2023044389-A1 | GELMA POLYMER COMPOSITIONS COMPRISING CORTICOSTEROIDS | GELMEDIX, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023044385-A1 | GELMA POLYMER COMPOSITIONS AND USES THEREOF | GELMEDIX, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| CN-115776887-A | MDM2 degrading agents and uses thereof | 凯麦拉医疗公司 | 2023-03-10 | — | — | CN | disclosed |
| WO-2023014361-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF PSYCHIATRIC DISORDERS | LA PHARMA TECH INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| CN-111108106-B | Heterocyclic derivatives as pest control agents | 拜耳公司 | 2023-02-03 | — | — | CN | disclosed |
| EP-4119231-A1 | LIQUID DISPENSER | Aptar Radolfzell GmbH (DE) | 2023-01-18 | — | — | EP | disclosed |
| WO-2022258988-A1 | NEW COMPOSITION COMPRISING IMMUNOMODULATORY DRUG | NANEXA AB (SE) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022258987-A1 | NEW FORMULATIONS COMPRISING AZACITIDINE | NANEXA AB (SE) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022258985-A1 | NEW FORMULATIONS COMPRISING BIOLOGIC ACTIVE DRUGS | NANEXA AB (SE) | 2022-12-15 | — | — | WO | disclosed |
| EP-3934653-B1 | AZELASTINE AS ANTIVIRAL TREATMENT | CEBINA GmbH (AT) | 2022-11-09 | — | — | EP | disclosed |
| US-11492625-B2 | C5a binding nucleic acids | APTARION BIOTECH AG (DE) | 2022-11-08 | — | — | US | disclosed |
| CN-111246743-B | Active ingredient combinations having insecticidal/acaricidal properties | 拜耳公司 | 2022-10-11 | — | — | CN | disclosed |
| WO-2022208146-A1 | NASAL COMPOSITIONS COMPRISING ALCAFTADINE | ALKEM LABORATORIES LIMITED (IN) | 2022-10-06 | — | — | WO | disclosed |
| US-20220273637-A1 | NOVEL PFAR-INHIBITING COMPOUNDS | Institut National de la Santé et de la Recherche Médicale (FR) | 2022-09-01 | — | — | US | disclosed |
| US-20220257847-A1 | IRRIGATION AND ASPIRATION DEVICE AND METHOD | AARDVARK MEDICAL, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| WO-2022173818-A1 | USE OF BILIVERDIN REDUCTASE B INHIBITORS TO ALLOW MALARIA ERADICATION IN PATIENTS WITH G6PD DEFICIENCY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-08-18 | — | — | WO | disclosed |
| US-11406736-B2 | Vascular extracellular matrix hydrogel | University of Pittsburgh—Of the Commonwealth Systems of Higher Education (US) | 2022-08-09 | — | — | US | disclosed |
| CN-109996799-B | Fused bicyclic heterocyclic derivatives as pest control agents | 拜耳作物科学股份公司 | 2022-07-19 | — | — | CN | disclosed |
| CN-114728928-A | Novel heteroaryl triazole compounds as pesticides | 拜耳公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-4021341-A1 | POLYMER-PERMEATED GRAFTS AND METHODS OF MAKING AND USING THE SAME | Bioaesthetics Corporation (US) | 2022-07-06 | — | — | EP | disclosed |
| US-11369760-B2 | Inhalation atomizer comprising a blocking function and a counter | ANOVENT PHARMACEUTICAL (U.S.), LLC (US) | 2022-06-28 | — | — | US | disclosed |
| CN-114641467-A | Substituted sulfonamides for controlling animal pests | 拜耳公司 | 2022-06-17 | — | — | CN | disclosed |
| US-20220183980-A1 | CARRIER-BINDING AGENT COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-06-16 | — | — | US | disclosed |
| US-20220152096-A1 | IODINE COMPOSITIONS | DERMALIQ THERAPEUTICS, INC. | 2022-05-19 | — | — | US | disclosed |
| EP-3996697-A1 | NOVEL PFAR-INHIBITING COMPOUNDS | Université de Bretagne Occidentale (U.B.O.) (FR) | 2022-05-18 | — | — | EP | disclosed |
| CN-114502545-A | Novel heteroaryl-triazole compounds as pesticides | 拜耳公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2022091925-A1 | ROPINIROLE-CONTAINING PATCH AND METHOD FOR IMPROVING SKIN PERMEABILITY OF ROPINIROLE | 久光製薬株式会社 | 2022-05-05 | — | — | WO | disclosed |
| WO-2022092284-A1 | COMPOSITION CONTAINING LIPID PEPTIDE AND SUCROSE ESTER | 日産化学株式会社 | 2022-05-05 | — | — | WO | disclosed |
| US-11318234-B2 | Irrigation and aspiration device and method | AARDVARK MEDICAL, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| WO-2022072696-A1 | COMPOSITIONS COMPRISING COMBINATIONS OF COLLAGEN OR ELASTIN POLYPEPTIDES WITH ACTIVE INGREDIENTS AND METHODS OF USING SAME | GELTOR, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| US-11291751-B2 | Irrigation and aspiration device and methods | AARDVARK MEDICAL, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| US-11273174-B2 | Iodine compositions | NOVALIQ GMBH (DE) | 2022-03-15 | — | — | US | disclosed |
| WO-2022051414-A1 | ANTIBODY-NANOPARTICLE COMPLEXES AND METHODS FOR MAKING AND USING THE SAME | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-03-10 | — | — | WO | disclosed |
| CN-106794227-B | Extracellular matrix compositions | HLI细胞疗法有限责任公司 | 2022-03-01 | — | — | CN | disclosed |
| US-20220054563-A1 | DOSING REGIME AND FORMULATIONS FOR TYPE B ADENOVIRUSES | AKAMIS BIO, INC. | 2022-02-24 | — | — | US | disclosed |
| WO-2022035388-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AZELASTINE AND RELEVANT EXCIPIENTS | PHARMACTİVE İLAÇ SANAYİ VE TİCARET A.Ş. (TR) | 2022-02-17 | — | — | WO | disclosed |
| EP-3953380-A1 | RECOMBINANT ELASTIN AND PRODUCTION THEREOF | Geltor, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| CN-114026265-A | Apparatus for forming a plurality of coated particles, method for forming a plurality of coated particles, coated particles | 南爱克萨股份公司 | 2022-02-08 | — | — | CN | disclosed |
| WO-2022025168-A1 | CONTROL OF ACTIVATION OF MAST CELLS AND BASOPHILS VIA COAGULATION/FIBRINOLYSIS SYSTEM AND COMPLEMENT, AND PHARMACEUTICAL USE THEREOF | 国立大学法人広島大学 | 2022-02-03 | — | — | WO | disclosed |
| WO-2022025168-A1 | CONTROL OF ACTIVATION OF MAST CELLS AND BASOPHILS VIA COAGULATION/FIBRINOLYSIS SYSTEM AND COMPLEMENT, AND PHARMACEUTICAL USE THEREOF | 国立大学法人広島大学 | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325383-A1 | Small Molecule Targeting of BRD4 for Treatment of COVID-19 | BRD4, BRD2, BICRA | HRH1 2153/4885ADRA1A 3575/4885ADRA1B 3125/4885 |
| US-20250064825-A1 | NASAL COMPOSITIONS COMPRISING ALCAFTADINE | CCL11, IL5, CMA1 | HRH1 6/4885ADRA1A 100/4885ADRA1B 133/4885 |
| US-20250064828-A1 | NASAL COMPOSITIONS COMPRISING ALCAFTADINE | CCL11, IL5, CMA1 | HRH1 6/4885ADRA1A 100/4885ADRA1B 133/4885 |
| US-20260007682-A1 | NASAL COMPOSITIONS COMPRISING ALCAFTADINE | MUC1, CFD, IL17A | HRH1 35/4885ADRA1A 406/4885ADRA1B 443/4885 |
| US-20260085120-A1 | Carrier-PD-L1 Binding Agent Compositions for Treating Cancers | CD274, PDCD1LG2, PDCD1 | HRH1 3398/4885ADRA1A 2122/4885ADRA1B 2284/4885 |
| US-11369760-B2 | Inhalation atomizer comprising a blocking function and a counter | ADRB2, ADRB1, ADRA2B | HRH1 502/4885ADRA1A 9/4885ADRA1B 5/4885 |
| US-20250064827-A1 | NASAL COMPOSITIONS COMPRISING ALCAFTADINE | CCL11, IL5, CMA1 | HRH1 6/4885ADRA1A 100/4885ADRA1B 133/4885 |
| US-20250064826-A1 | NASAL COMPOSITIONS COMPRISING ALCAFTADINE | CCL11, IL5, CMA1 | HRH1 6/4885ADRA1A 100/4885ADRA1B 133/4885 |
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | DHFR, CCNH, ODC1 | HRH1 811/4885ADRA1A 4750/4885ADRA1B 4660/4885 |
| US-20230332148-A1 | DISCONTINUOUS OLIGONUCLEOTIDE LIGANDS | NSUN3, NSUN2, RBM3 | HRH1 2379/4885ADRA1A 2955/4885ADRA1B 3304/4885 |
| US-20230142221-A1 | COMPOSITIONS AND METHODS FOR MODULATING ACE2 RECEPTOR | ACE2, ACE, AGTR2 | HRH1 2618/4885ADRA1A 376/4885ADRA1B 480/4885 |
| US-20240173331-A1 | NASAL COMPOSITIONS COMPRISING ALCAFTADINE | CCL11, IL5, CMA1 | HRH1 6/4885ADRA1A 100/4885ADRA1B 133/4885 |
| US-12274702-B2 | Nasal compositions comprising alcaftadine | CCL11, IL5, CMA1 | HRH1 6/4885ADRA1A 100/4885ADRA1B 133/4885 |
| US-20260014147-A1 | STAT6 DEGRADERS | STAT6, NCOR1, CBR1 | HRH1 10/4885ADRA1A 465/4885ADRA1B 598/4885 |
| US-20230201216-A1 | AZELASTINE AS ANTIVIRAL TREATMENT | ZC3HAV1, ZC3HAV1L, RPL35 | HRH1 196/4885ADRA1A 761/4885ADRA1B 1002/4885 |
| US-20230218630-A1 | COMBINATION OF ALCAFTADINE AND A CORTICOSTEROID | CCL11, IL5, TSLP | HRH1 19/4885ADRA1A 81/4885ADRA1B 92/4885 |
| US-20230158167-A1 | SITE-SPECIFIC ANTIBODY CONJUGATION AND ANTIBODY-DRUG CONJUGATE AS SPECIFIC EMBODIMENT THEREOF | EEA1, CD47, FCGR2A | HRH1 2296/4885ADRA1A 1329/4885ADRA1B 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.